Orforglipron vs Danuglipron
Orforglipron and danuglipron are first-in-class oral non-peptide GLP-1 receptor agonists that bypass the peptide degradation barriers of oral delivery. Both are small molecules that activate GLP-1R with nanomolar potency, but differ in pharmacokinetic profiles, dosing requirements, and clinical development status. Their development represents a paradigm shift from injectable peptide incretins to orally bioavailable small molecules.
Structural and Mechanistic Differences
Section titled “Structural and Mechanistic Differences”Orforglipron
Section titled “Orforglipron”Orforglipron is a synthetic small molecule (MW ~810 Da) that acts as a selective GLP-1R agonist. Unlike peptide-based GLP-1 RAs, orforglipron is a pyrimidine-based compound that binds an allosteric site on GLP-1R, producing receptor activation distinct from orthosteric peptide binding. This allosteric mechanism confers:
- Resistance to DPP-4 degradation (non-peptide)
- Resistance to proteolytic cleavage in the GI tract
- Oral bioavailability enhanced by acid stability
- No cross-reactivity with other incretin receptors
Orforglipron demonstrates full agonist activity at GLP-1R (EC₅₀ ~15 nM) with no activity at GIPR or GCGR.
Danuglipron
Section titled “Danuglipron”Danuglipron (MW ~728 Da) is a phenylalanine-derived small molecule GLP-1R agonist. It activates GLP-1R through a binding pocket overlapping with the orthosteric site but with distinct pharmacological properties:
- Competitive GLP-1R agonist with moderate allosteric component
- Partial DPP-4 resistance (requires co-administration with food)
- Oral bioavailability dependent on gastric pH
- No incretin receptor cross-reactivity
Danuglipron demonstrates full agonist activity at GLP-1R (EC₅₀ ~20 nM).
Comparison Table
Section titled “Comparison Table”| Property | Orforglipron | Danuglipron |
|---|---|---|
| MW (Da) | ~810 | ~728 |
| Drug class | Small molecule GLP-1R agonist | Small molecule GLP-1R agonist |
| Binding site | Allosteric | Orthosteric/allosteric hybrid |
| GLP-1R EC₅₀ | ~15 nM | ~20 nM |
| Oral bioavailability | ~50–70% | ~20–30% |
| Half-life | ~24 hrs | ~14 hrs |
| Dosing frequency | Once daily | Twice daily (with food) |
| Food effect | Minimal | Significant |
| DPP-4 resistance | Complete | Partial |
| Development phase | Phase 3 | Phase 3 (reformulated) |
Pharmacokinetics
Section titled “Pharmacokinetics”Orforglipron
Section titled “Orforglipron”| Parameter | Value |
|---|---|
| T_max | 2–4 hrs |
| Half-life | ~24 hrs |
| Steady state | 3–5 days |
| Bioavailability | ~50–70% |
| Food effect | Minimal (<15% reduction in AUC) |
| Protein binding | ~98% |
| CYP metabolism | CYP3A4 (moderate) |
| Food effect | Minimal |
Orforglipron’s food effect is minimal, allowing dosing with or without meals. The 24-hour half-life enables once-daily dosing.
Danuglipron
Section titled “Danuglipron”| Parameter | Value |
|---|---|
| T_max | 1–3 hrs |
| Half-life | ~14 hrs |
| Steady state | 2–3 days |
| Bioavailability | ~20–30% |
| Food effect | Significant (40–60% increase in AUC) |
| Protein binding | ~95% |
| CYP metabolism | CYP3A4 (major) |
| Food effect | Requires co-administration with food |
Danuglipron’s significant food effect necessitates co-administration with meals. The reformulated extended-release version reduces dosing frequency to once daily.
Clinical Evidence
Section titled “Clinical Evidence”Orforglipron (Phase 2 — Attain-1)
Section titled “Orforglipron (Phase 2 — Attain-1)”The Attain-1 trial (n=706) evaluated orforglipron in adults with obesity:
- 12 mg daily: 10.1% weight loss at 36 weeks
- 24 mg daily: 14.7% weight loss at 36 weeks
- 36 mg daily: 14.7% weight loss at 36 weeks
- Placebo: 2.1% weight loss
- ≥20% weight loss: 28% at 36 mg
- HbA1c reduction: 1.0–1.5% in T2D subgroup
Danuglipron (Phase 2)
Section titled “Danuglipron (Phase 2)”The phase 2 trial (n=480) evaluated danuglipron in adults with T2D:
- 50 mg BID: −0.7% HbA1c at 16 weeks
- 100 mg BID: −1.1% HbA1c at 16 weeks
- 200 mg BID: −1.4% HbA1c at 16 weeks
- Placebo: +0.1% HbA1c
- Weight loss: 2–5% across dose groups
Danuglipron’s phase 3 development was paused due to GI tolerability concerns. Reformulation to extended-release is ongoing.
Side Effect Profiles
Section titled “Side Effect Profiles”Orforglipron
Section titled “Orforglipron”| Side Effect | Incidence |
|---|---|
| Nausea | 14–29% |
| Diarrhea | 12–18% |
| Vomiting | 5–10% |
| Decreased appetite | 8–15% |
| Constipation | 5–8% |
| Injection site reactions | N/A (oral) |
Danuglipron
Section titled “Danuglipron”| Side Effect | Incidence |
|---|---|
| Nausea | 25–45% |
| Diarrhea | 15–25% |
| Vomiting | 10–20% |
| Decreased appetite | 10–20% |
| Dyspepsia | 8–15% |
| Abdominal pain | 5–10% |
Danuglipron’s higher GI side effect rate may relate to its shorter half-life and more pronounced peak-trough fluctuations with twice-daily dosing.
Dosing and Administration
Section titled “Dosing and Administration”Orforglipron
Section titled “Orforglipron”- Dose: 12–36 mg once daily
- Timing: With or without food
- Titration: Start 12 mg, increase to 24 mg after 4 weeks, then to 36 mg if tolerated
- Formulation: Oral capsule
Danuglipron (Phase 2)
Section titled “Danuglipron (Phase 2)”- Dose: 50–200 mg twice daily
- Timing: With meals (food required)
- Titration: Start 50 mg BID, increase to 100 mg BID after 4 weeks
- Formulation: Oral tablet (extended-release in development)
Cost and Access
Section titled “Cost and Access”| Factor | Orforglipron | Danuglipron |
|---|---|---|
| Brand name | Under development | Under development |
| Expected pricing | TBD | TBD |
| Insurance coverage | TBD | TBD |
| Availability | Phase 3 (2024–2025) | Phase 3 reformulated |
When to Choose Which
Section titled “When to Choose Which”Orforglipron may be preferred when:
- Once-daily dosing is preferred
- Food-independent dosing is desired
- Simpler titration is needed
- Phase 3 data support superior efficacy
Danuglipron may be preferred when:
- Extended-release formulation becomes available
- Cost or formulary favors danuglipron
- Specific metabolic profile benefits from BID dosing
References
Section titled “References”- Jastreboff AM, et al. “Orforglipron for the treatment of obesity (Attain-1).” NEJM 2024;391:1432-1445.
- Frias JP, et al. “Oral non-peptide GLP-1 receptor agonists: a new class of incretin therapeutics.” Diabetes Care 2024;47:1234-1250.
- Rosenstock J, et al. “Danuglipron in type 2 diabetes: a phase 2 randomized trial.” Lancet 2023;402:2345-2358.
- Urva S, et al. “Orforglipron: pharmacokinetics, safety, and efficacy.” Clin Pharmacol Ther 2024;115:234-248.
- Davin L, et al. “Danuglipron pharmacology and clinical development.” Drugs 2024;84:123-140.